Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - December 2018

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Brivaracetam (Briviact®) has been accepted for restricted use as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from 4 years to ≤15 years of age with epilepsy. The restrictions limits use to patients with refractory epilepsy and treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy.

Ciclosporin eye drops (Verkazia®) have been accepted for use in the treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents (until the age of 18)

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - December 2018' on Email Share 'SMC Update - December 2018' on Delicious Share 'SMC Update - December 2018' on Digg Share 'SMC Update - December 2018' on Facebook Share 'SMC Update - December 2018' on reddit Share 'SMC Update - December 2018' on StumbleUpon Share 'SMC Update - December 2018' on Twitter

CKS Updates - November 2018

During November 2018 Clinical Knowledge Summaries were published or updated in the following areas.

The following topics were all reviewed:

All of reviewed topics have undergone reviews and minor restructures.

Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.

Share 'CKS Updates - November 2018' on Email Share 'CKS Updates - November 2018' on Delicious Share 'CKS Updates - November 2018' on Digg Share 'CKS Updates - November 2018' on Facebook Share 'CKS Updates - November 2018' on reddit Share 'CKS Updates - November 2018' on StumbleUpon Share 'CKS Updates - November 2018' on Twitter

NICE Guidance - November 2018

The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of November 2018. This month there are two guidelines that impact upon primary care.

The Heavy menstrual bleeding guideline has been updated. The update reinstates recommendations on ulipristal acetate (Esmya®) following a European Medicines Agency review. Information on shared decision making and monitoring for side effects has been added for this treatment option.

The Urinary tract infection (catheter-associated): antimicrobial prescribing guideline has also been published. It sets out an antimicrobial prescribing strategy for catheter-associated urinary tract infection in children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

Last month several similar guidelines were issued that were not included in last month's post, they are as follows:

As above, each aims to provide an antimicrobial prescribing strategy that aims to optimise antibiotic use and reduce antibiotic resistance.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - November 2018' on Email Share 'NICE Guidance - November 2018' on Delicious Share 'NICE Guidance - November 2018' on Digg Share 'NICE Guidance - November 2018' on Facebook Share 'NICE Guidance - November 2018' on reddit Share 'NICE Guidance - November 2018' on StumbleUpon Share 'NICE Guidance - November 2018' on Twitter

CKS Updates - October 2018

During October 2018 Clinical Knowledge Summaries were published or updated in the following areas.

The following topics were all reviewed:

The majority of reviewed topics have undergone reviews and minor restructures.

The most significant changes were to the Bell's palsy topic where have been changes to the recommendations on use of antiviral treatment in combination with corticosteroids and referral and the Polycystic ovary syndrome topic where recommendations on the diagnosis of polycystic ovary syndrome (PCOS) in adolescents have been updated in line with guidance issued by the International PCOS Network.

Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.

Share 'CKS Updates - October 2018' on Email Share 'CKS Updates - October 2018' on Delicious Share 'CKS Updates - October 2018' on Digg Share 'CKS Updates - October 2018' on Facebook Share 'CKS Updates - October 2018' on reddit Share 'CKS Updates - October 2018' on StumbleUpon Share 'CKS Updates - October 2018' on Twitter

NICE Guidance - October 2018

The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of October 2018. This month there are two guidelines that impact upon primary care.

The Lyme disease guideline has been updated correcting the information relating to treatments for Lyme carditis in children aged 9 to 12 who are haemodynamically unstable.

The Decision-making and mental capacity guideline has been published. It covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - October 2018' on Email Share 'NICE Guidance - October 2018' on Delicious Share 'NICE Guidance - October 2018' on Digg Share 'NICE Guidance - October 2018' on Facebook Share 'NICE Guidance - October 2018' on reddit Share 'NICE Guidance - October 2018' on StumbleUpon Share 'NICE Guidance - October 2018' on Twitter

« Older Posts

Prescribing Advice for GPs is powered by ClassicPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer